Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 12/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 8/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929231 | 0.96 | ATM (0.45) | ATMPIK3C3ATRROCK2ROCK1 | |
| SCHEMBL1463669 | 0.82 | SLC6A2 (0.38) | — | |
| SCHEMBL6709256 | 0.74 | TSHR (0.52) | ATM | |
| SCHEMBL18258630 | 0.69 | CHI3L1 (0.52) | — | |
| SCHEMBL5152847 | 0.68 | MC4R (0.49) | ATMPIK3C3 | |
| SCHEMBL16488227 | 0.68 | HTR6 (0.54) | — | |
| SCHEMBL11466316 | 0.68 | MC4R (0.46) | — | |
| SCHEMBL8565864 | 0.68 | MC4R (0.46) | — | |
| SCHEMBL3764570 | 0.68 | HTR6 (0.54) | — | |
| SCHEMBL11371130 | 0.68 | ABHD6 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807691-B2 | Substituted N-arylpyrrolidines as selective androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1891038-B1 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | ELI LILLY AND COMPANY | 2008-07-24 | — | — | US | disclosed |
| EP-1891038-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006124447-A2 | SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176864-A1 | Substituted N-Arylpyrrolidines as Selective Androgen Receptor Modulators | AR, FSHR, SHBG | ATM 685/4885PIK3C3 3466/4885ATR 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.